arrow
D

Douglas D. Leipold

roche holding
H指数:24
被引数:3,331

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Leveraging Buprenorphine and Halofantrine as Tool Molecules to Develop a Novel Semi-Physiologically based Pharmacokinetic Model Accounting for Gastro-Intestinal Lymphatic Absorption and Enabling Cross-Species Translation

利用Buprenorphine和Halofantrine作为工具分子,开发一种新型半生理学基础的药代动力学模型,该模型考虑了胃肠淋巴吸收并能够实现跨物种转化。

2025-03-260
OA
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
2024-01-119
OAAI
Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
2022-04-0110
OAAI
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides
2022-01-0132
OAAI
Calicheamicin Antibody-Drug Conjugates with Improved Properties
2021-03-1522
OA
An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models
2021-02-058
OAAI
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

嵌合BET降解剂的抗体偶联可实现体内活性

2019-11-14141
PREAI
Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo
2019-04-1016
PREAI
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
2019-02-0449
OAAI
Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
MABS
IF7.3
2018-10-0213
OAAI
Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates
2017-07-1353
PREAI
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers
2017-05-0260
OAAI